Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

MedPharm, Molecular Profiles Form Alliance

By Drug Discovery Trends Editor | August 27, 2012

MedPharm, a specialist pharmaceutical development company, recognised internationally for its expertise in topical drug delivery systems and Molecular Profiles, a leading specialist contract development and clinical trial manufacturing organisation, announced that they have formed a strategic alliance. The new alliance branded as MPGMP, provides an enhanced service for the manufacture of topical formulation clinical trial material.

Both companies share a record of successfully handling challenging compounds; something that is critical for topical formulations which often require small batch dosage forms and complicated compound analysis. Together, Molecular Profiles and MedPharm can work on the manufacture of a range of pharmaceutical products including more complex new chemical entities (NCEs), manufacturing clinical trial supplies at relatively small batch sizes to get to proof of concept in clinical trials (Phase 2) as early as possible.

Andrew Muddle, CEO at MedPharm Ltd comments: “We are pleased to announce our strategic alliance in GMP clinical trial supplies with Molecular Profiles and look forward to offering a seamless end-to-end topical formulation development service to our clients. MedPharm’s aim is to continue to build on its reputation as a specialist topical pharmaceutical company concentrating on the development of products for dermatology and other topical indications. Our partnership with Molecular Profiles will help us to drive this aim forward, offering strengthened expertise and an expanded range of GMP services enabling the provision of clinical trial services to our clients.”

Nikin Patel, CEO at Molecular Profiles adds: “The alliance with MedPharm, is an opportunity for both companies to expand our service offerings within topical drug delivery.  Under our expansion program, we remain committed to providing our clients with access to the best innovation and manufacturing expertise. We are confident that together we can deliver a high end service.”

Date: August 20, 2012
Source: Molecular Profiles

 


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE